Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Lorlatinib is a third-generation dual-target inhibitor of ALK/ROS1, primarily in···【more】
Release date：2026-01-23Recommended：235
The price of lorlatinib varies significantly, mainly depending on the drug sourc···【more】
Release date：2026-01-23Recommended：224
This drug is a prescription medicine. Its use must strictly follow the doctor’s ···【more】
Release date：2026-01-23Recommended：218
The price of Lorlatinib is subject to significant fluctuations due to the impact···【more】
Release date：2026-01-23Recommended：206
The monthly treatment cost of lorlatinib currently available in China fluctuates···【more】
Release date：2026-01-23Recommended：282
Pfizer recently announced that the U.S. Food and Drug Administration (FDA) has a···【more】
Release date：2026-01-23Recommended：255
On March 3, 2021, Pfizer announced that the U.S. Food and Drug Administration (F···【more】
Release date：2026-01-23Recommended：303
At the Presidential Symposium of the 2020 ESMO Annual Congress, results of a hea···【more】
Release date：2026-01-23Recommended：210
In December 2020, the U.S. Food and Drug Administration (FDA) accepted a supplem···【more】
Release date：2026-01-23Recommended：280
Pfizer recently announced that the Phase III CROWN study, which evaluates Lorbre···【more】
Release date：2026-01-23Recommended：226
Lorbrena (generic name: Lorlatinib) is a next-generation tyrosine kinase inhibit···【more】
Release date：2026-01-23Recommended：265
On November 19, 2020, Pfizer announced the positive results of the phase III hea···【more】
Release date：2026-01-23Recommended：235
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
